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Acute massive myelofibrosis with acute
lymphoblastic leukemia
Akut masif myelofibrozis ve akut lenfoblastik lösemi birlikteliği
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Abstract
Acute myelofibrosis is characterized by pancytopenia of sudden onset, megakaryocytic hyperplasia, extensive bone mar-
row fibrosis, and the absence of organomegaly. Acute myelofibrosis in patients with acute lymphoblastic leukemia is 
extremely rare. We report a 4 -year-old boy who was diagnosed as having acute massive myelofibrosis and acute lym-
phoblastic leukemia. Performing bone marrow aspiration in this patient was difficult (a “dry tap”), and the diagnosis was 
established by means of a bone marrow biopsy and immunohistopathologic analysis. The prognostic significance of acute 
myelofibrosis in patients with acute lymphoblastic leukemia is not clear. (Turk J Hematol 2009; 26: 204-6)
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Özet
Akut myelofibrozis ani gelişen pansitopeni, kemik iliğinde megakaryositik hiperplazi, belirgin fibrozis ve organomegali 
olmaması ile karakterize bir hastalıktır. Akut myelofibrozis ile akut lenfoblastik lösemi birlikteliği çok nadir görülmektedir. 
Burada akut masif myelofibrozis ve akut lenfoblastik lösemi tanısı alan 4,5 yaşında erkek hasta sunuldu. Kemik iliği aspira-
syonu yapılamayan (“kuru ilik”) hastanın tanısı, ancak kemik iliği biyopsisi ve immünohistopatolojik inceleme ile konabildi. 
Akut myelofibrozisin akut lenfoblastik lösemide prognostik önemi tam bilinmemektedir. (Turk J Hematol 2009; 26: 204-6)
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Introduction
Idiopathic primary myelofibrosis is a chronic disorder 
characterized by bone marrow fibrosis, extramedullary 
hematopoiesis, and a leukoerythroblastic blood profile, and it is 
usually classified as a myeloproliferative syndrome. A rapidly 
progressive form of myelofibrosis, called “malignant myelofibrosis” 
or “acute myelofibrosis (AMF)”, is characterized by pancytopenia 
of sudden onset, megakaryocytic hyperplasia, excessive marrow 
fibrosis, and the absence of hepatosplenomegaly [1-3]. Primary 
myelofibrosis also occurs in those with acute leukemia (especially 
the myelocytic types); however, AMF that develops in individuals 
with acute lymphoblastic leukemia (ALL) is extremely rare. We 
report a 4 -year-old boy diagnosed with AMF and ALL.Case Report 
A 4 -year-old boy who presented with a one-month history of 
fever, fatigue, and abdominal pain was initially diagnosed as 
having typhoid fever and was treated with ceftriaxone for seven 
days. He was referred to our clinic because of coexisting anemia 
and leukopenia. This child was a monozygotic twin born to healthy 
nonconsanguineous parents, and his growth and development 
were within normal limits. His vital signs at admission were as 
follows: body temperature 38.4ºC, blood pressure 100/60 mmHg, 
and pulse rate 120 bpm. The initial physical examination did not 
reveal lymphadenopathy or hepatosplenomegaly. This patient 
demonstrated no phenotypic signs of Down syndrome or 
mosaicism. The results of a complete blood count revealed the 
following values: white blood cell count, 3.6 x 109/L (26% 
neutrophils, 7% monocytes, 64% lymphocytes, and 3% blasts); 
hemoglobin, 8.9 g/dl; platelet count, 315 x 109/L; and reticulocyte 
count, 0.93%. The results of serum biochemical analyses were all 
within the normal range, except for the serum lactate dehydrogenase 
level, which was 634 IU/L (normal range: 150-500 IU/L). The 
sedimentation rate was 120 mm/h, and the level of C-reactive 
protein was 168 mg/dl (normal range, 0-10 mg/dl). Direct 
Coombs’ test and an antinuclear antibody test were negative, and 
the levels of serum immunoglobulins G, M, and A as well as 
complements 3 and 4 were within the reference range. Chest 
radiograph and abdominal ultrasonographic findings were 
unremarkable. The results of viral serologic testing, including that 
for Epstein-Barr virus (EBV), cytomegalovirus (CMV), parvovirus 
B19, human immunodeficiency virus (HIV), and hepatitis A, B, and 
C, were negative, as were the results of the Widal test for 
Salmonella  and the Wright agglutination test for Brucella. The 
bone marrow aspiration was a dry tap in each of three consecutive 
attempts. The bone marrow biopsies revealed a diffuse blastic 
infiltration (Figure 1). On immunohistopathologic examination, the 
blasts were positive for CD34, CD10, TdT, CD20, and CD79a. The 
results of staining for CD3, CD41, CD43, CD56, CD117, and 
myeloperoxidase were negative. The reticulin fibers were increased 
in number, especially at sites in which neoplastic infiltration was 
intense (Figure 2). Conventional cytogenetic and fluorescent in situ 
hybridization (FISH) analyses were performed from deparaffinized 
bone marrow biopsy. Unstimulated bone marrow lymphocyte 
cultures were set up for incubation time of 48 and 72 hours, and 
metaphase spreads were examined after harvesting and GTG 
banding according to standard protocols. Three metaphases were 
found and revealed a 46, XY karyotype. FISH studies were also 
performed with probes specific for 5q31, 7q31, BCR-ABL fusion, 
and t(15;17) (Vysis, Downers Grove, IL, USA), and revealed normal 
signals except for an extra signal with the translocation probe 
t(8;21) (Vysis, Downers Grove, IL, USA) for chromosome 21q22 
region in 22% of the cells. With the extra signal for 21q22, we 
decided to perform chromosome analysis from peripheral blood 
and skin biopsy samples of the patient, which revealed normal 
karyotypes.
The patient was diagnosed as having B-cell ALL with acute 
massive myelofibrosis. He is currently being treated according to 
the Berlin-Frankfurt-Munster (BFM) 95 treatment protocol for ALL. 
On day 15 of the chemotherapy, repeated bone marrow aspiration 
was a dry tap. A bone marrow biopsy showed necrosis between 
bone trabeculae and significant fibrosis, as well as an increased 
number of reticulin fibers and no hematopoietic cells. At day 33 of 
the chemotherapy regimen, a bone marrow biopsy revealed 
persisting necrosis with foci of immature bone formation and 
massive collagen fibrosis. No hematopoietic cells were noted. At 
day 70 of the chemotherapy and before continuation therapy, a 
bone marrow aspiration and biopsy showed normal hematopoietic 
cells and no fibrosis. At the time of this writing (20 months after 
diagnosis), the patient is still in clinical  remission and is being 
treated with a continuation chemotherapy regimen.
Written informed consent was obtained from the patient and 
the family. 
Discussion
Acute myelofibrosis is known to progress to various types of 
acute myeloid leukemia and chronic myelogenous leukemia. Of 
particular interest is the rare termination of AMF as ALL, which has 
been reported in two pediatric patients. In one of those children, 
AMF terminated as ALL of T-cell origin, and in the other, AMF 
terminated as null-type ALL [4,5]. In addition to those two cases, 
Abla and Ye [1] recently reported a child with B-ALL and AMF. 
They did not know whether or not myelofibrosis was present 
previously and terminated to ALL in that patient, but his massive 
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Figure 2. Reticulin stain showing an increased number of fibers at the time of 
diagnosis (original magnification x 400)
Figure 1. Bone marrow biopsy showing a diffuse infiltrate of lymphoblasts (hema-
toxylin-eosin stain, original magnification x 400)myelofibrosis was most likely due to secretion of cytokines from 
blastic cells. The same situation was probably present in our case. 
To our knowledge, only four adult patients with AMF terminating 
as ALL have been described in the literature [2,3,6,7]. Three of 
seven reported cases including both children and adults in the 
literature died within two months of diagnosis. However, it is 
difficult to determine the prognostic significance of AMF in patients 
with ALL due to small number of cases reported to date. 
Cytogenetic studies of patients with myelofibrosis have shown 
that the presence of 13q-, 20q-, +8, and abnormalities of 
chromosomes 1,7 and 9 constitute more than 80% of the 
chromosomal changes in those individuals and suggest that in 
many patients, gene loss and/or inactivation may be an important 
pathogenetic mechanism in the development of myelofibrosis [8]. 
Cytogenetic analysis of peripheral blood and skin fibroblast 
cultures in our patient revealed a 46,XY genotype. However, the 
results of a FISH analysis from bone marrow confirmed the 
presence of trisomy 21 in 22% of the cells in our patient. It is well 
known that AMF is associated with Down syndrome [9].  Our 
patient did not have any phenotypic or karyotypic feature of Down 
syndrome. Although we did not detect a karyotype abnormality in 
the peripheral blood and skin fibroblast culture, we concluded that 
there could be a cryptic chromosome abnormality limited to the 
leukemic cell population, and the extra copy of chromosome 
region 21q22 could be responsible for the myelofibrosis.
Finally, it should be remembered that dry taps are caused by 
a marked increase in reticulin fibrosis. In patients who experience 
that difficulty, bone marrow biopsy can be of great help in making 
an accurate diagnosis, as in our patient.
No author of this paper has a conflict of interest, including 
specific financial interests, relationships, and/or affiliations relevant 
to the subject matter or materials included in this manuscript.
References
1.  Abla O, Ye CC. Acute lymphoblastic leukemia with massive 
myelofibrosis. J Pediatr Hematol Oncol 2006;28:633-4.
2.  Amjad H, Gezer S, Inoue S, Bollinger RO, Kaplan J, Carson S, 
Bishop CR. Acute myelofibrosis terminating in an acute lympho-
blastic leukemia: a case report. Cancer 1980;46: 615-8.
3.  Dunphy CH, Kitchen S, Saravia O, Velasquez WS. Acute myelo-
fibrosis terminating in acute lymphoblastic leukemia: case report 
and review of the literature. Am J Hematol 1996;51:85-9.
4.  Chen JS, Lin DT, Chuu WM, Lin KH, Su IJ, Lin KS. Acute myelo-
fibrosis terminating in acute lymphoblastic leukemia: report of 
one case. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 
1992;33:136-43.
5.  Marino R, Altshuler G, Humphrey GB. Idiopathic myelofibrosis 
followed by acute lymphoblastic leukemia. Am J Dis Child 
1979;133:1194-5. 
6.  Polliack A, Prokocimer M, Matzner Y. Lymphoblastic leukemic 
transformation (lymphoblastic crisis) in myelofibrosis and myeloid 
metaplasia. Am J Hematol 1980;9:211-20.
7.  Amberger DM, Saleem A, Kemp BL, Truong LD. Acute myelofi-
brosis-a leukemia of pluripotent stem cell. A report of three cases 
and review of the literature. Ann Clin Lab Sci 1990;20:409-14.
8.  Reilly JT. Cytogenetic and molecular genetic aspects of idio-
pathic myelofibrosis. Acta Haematol 2002;108:113-9.
9.  Awasthi A, Das R, Varma N, Ahluwalia J, Gupta A, Marwaha RK, 
Garewal G. Hematological disorders in Down syndrome: ten-year 
experience at a tertiary care centre in North India. Pediatr 
Hematol Oncol 2005;22:507-12.
Avcı et al.
Acute myelofibrosis with ALL Turk J Hematol 2009; 26: 204-6 206